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Predicting end-stage renal disease: Bayesian perspective of in- pertension and proteinuria, by tight blood pressure con-
formation transfer in the clinical decision-making process at trol and inhibition of the renin-angiotensin system. To
the individual level. this purpose, early referral to a nephrologist is importantBackground. Predicting outcomes such as end-stage renal
to identify patients at risk [1] and provide individualizeddisease (ESRD) by integration and better utilization at individ-
and comprehensive care [2] aimed to slow disease pro-ual level of epidemiologic data may facilitate clinical decision-
making processes. gression and limit or prevent the occurrence of ESRD
Methods. To predict individual ESRD risk in an average and related complications.
patient in the United States, ESRD prevalence and levels of
Evidence-based medical (EBM) practice, optimizationuncertainty and conditional risk factors independence were
of care, and cost-effective approaches are the milestonesconsidered by population data (1998) and pooled analysis of 11
randomized trials. Data integration and input were by decision- to transfer available knowledge in the decision-making
tree simulation approach (simple, parallel, and sequential sce- process. As an algorithm, this process includes four con-
narios) and Bayes’ theorem. Sensitivity analysis and risk pro- secutive steps: (1) asking answerable questions; (2) ac-files were employed to address uncertainty and assess different
cessing the best information; (3) appraising the validityrisk factor combinations. A health state values, associated with
and relevance of data; and (4) applying the informationESRD outcome levels, were taken from the literature.
Results. In this theoretical study, we provided a scholarly to patient care. This approach may have major clinical
example about the use of two known risk factors (urinary pro- implications since EBM decisions are definitely proven
tein 3 g/day and systolic blood pressure140 mm Hg) to pre- to be more cost-effective than clinical decisions relyingdict individual ESRD risk in an average patient in the United
primarily on subjective beliefs [3–7]. A given outcomeStates. The highest posterior (decisional) probability of ESRD
can be reliably predicted on the basis of objective andoccurrence (risk of 3.61% to 5.07%) in the individual patient
was associated with the worst health state, as assessed by multi- easily available information on patient origin and demo-
dimensional scenarios when both risk factors were present. graphic characteristics, presence/absence of risk factors
Conclusion. Decision tree models through an empirical
and disease prevalence in the population from where theBayesian approach may serve to predict the individual ESRD
individual patient comes (i.e., a reference population)risk on the basis of simple epidemiologic, demographic, and
clinical information that is easily available already at the first [8]. However, this “objective prior belief” is not directly
patient evaluation. applicable at the individual level. For instance, even very
precise estimates of the cumulative risk of ESRD in a
given (United States) population [9] cannot be used di-
Progression of chronic nephropathies to end-stage re- rectly in the clinical practice, since they assume a con-
nal disease (ESRD) can be slowed or prevented by early stant risk over years and, in the same time, do not contain
detection and control of risk factors, such as arterial hy- information about the individual constellation of risk fac-
tors. Thus, novel, more relevant algorithms are needed
to better assess individual outcomes and risks and toKey words: ESRD, risk factors, decision-tree models, Bayesian approach,
individual risk, probability. optimize transferring the best available information from
population to individual level [10].
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Fig. 1. Simple decision tree model of the risk of occurrence of end-
stage renal disease (ESRD) in average United States patient when the
increased level of proteinuria is considered as a risk factor. Simple
decision tree with ESRD as an outcome with two levels (Yes and No)
and proteinuria as a (risk) factor with two levels (Present, a risk factor
level when urinary protein 3 g/day; Absent, no-risk factor level when
Fig. 2. Parallel decision tree model of the risk of occurrence of end-urinary protein 3 g/day). The related a priori assumptions and proba-
stage renal disease (ESRD) in average United States patient when twobilities on branches and nodes of the tree are shown: (1) a priori
risk factors are considered. Multifactorial decision tree model withinformation (e.g., ESRD prevalence rate as an a priori probability of
parallel consideration of information on risk factors (i.e., four combina-0.001156, at the root chance node) and (2) decisional probabilities
tions of the factor levels) and computation of posterior probabilitiesinclude posterior probabilities (i.e., individual probabilities or risk when
(branches, terminal nodes). Symbols are: () chance nodes; () terminalexpressed in percentages, at the branches) and path probabilities (i.e.,
nodes. For other attributes see descriptions and definitions on Fig. 1.the chance of reaching a node, as probability “P,” shown here only on
the right side of the terminal nodes). Symbols are: () chance nodes;
() terminal nodes.
outcome given that conditions (e.g., risk factors) are
known a priori (e.g., prior beliefs and/or informativein facilitating the procedures and improving the decision-
priors) with preference-based values (e.g., costs) for eachmaking quality in time-critical situations or in shortage
level of the outcome [11, 21]. The approach consists ofof objective information [11, 12], where best available
(1) defining, structuring, and describing the problem ofevidence and patient’s unique circumstances and prefer-
predicting ESRD at individual level by a decision treeences can be integrated into a plan for optimal care
model with chance and terminal (output) nodes (Fig. 1);management [4, 13, 14]. More specifically, this approach
(2) collecting and assessing (e.g., at initial visit) the nec-generates new knowledge, provides justification and ex-
essary a priori information (i.e., ESRD prevalence, rela-planations for the decisions to be taken, and eventually
tionships with known risk factors—heavy proteinuriaensures a reliable objective knowledge-based reasoning
and increased blood pressure); and (3) revising the a priorito optimize the decision-making process [5, 6, 15, 16].
information by Bayes’ theorem and analyzing the modelFor instance, new principles and methods such as deci-
for computing decisional (posterior and path) probabili-sion trees or artificial intelligence network models may
ties (Figs. 1 to 3). The final outcome is the individual riskhelp to address the complexity and uncertainty of the
of ERSD given the presence or absence of specific riskdevelopment of chronic nephropathies and progression
factors and/or their combination. The background of theto ESRD [17–20].
Bayesian decision tree approach and its detailed con-In this theoretical study, we explored the performance
cepts and implications in the decision-making process inof a novel approach that integrates information coming
chronic renal disease follow.from various sources at the initial clinical evaluation,
Clinical decision-making process. Evidence-basedaddresses data uncertainty, and makes more valuable the
knowledge with decision analysis allows a more efficientup-to-date disease prevalence information. This method-
use of resources that mitigate against simplistic schemesologic framework also aims at providing a scholarly ex-
of health care rationing. The power of decision analysisample of how clinically objective evidence about the
is in its ability to offer an explicit and systematic approachinterplay of two well-established risk factors (heavy pro-
to decision making based on the premise of rationalityteinuria and high blood pressure) could be transferred
[22]. A rational decision-making process is choosing amonginto useful knowledge to predict ESRD in the individual
alternatives in a way that properly accords with prefer-patient.
ence-based values such as costs and/or health-related
quality-of-life estimates. It acknowledges choices and
METHODS their associated uncertainties to improve the use of em-
Algorithm of the patient-centered approach pirical data and preferences (e.g., for use in cost-effec-
(Bayesian perspective) tiveness analysis) (Fig. 4).
Clinical decision-making protocols, when driven by pa-The Bayesian decision-tree approach is built upon the
concept of computing decisional probabilities of disease tient data, provide individualized, patient-specific guide-
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Fig. 3. Sequential decision tree model of the
risk of occurrence of end-stage renal disease
(ESRD) in average United States patient when
two risk factors are considered. Multifactor-
ial decision tree model with sequential (con-
secutive) input of information on risk factors
and computation of posterior probabilities
(branches, terminal nodes). Symbols are: ()
chance nodes; () terminal nodes. For other
attributes see descriptions and definitions on
Fig. 1.
reduction of uncertainty about the model, given the data.
Moreover, it encodes all uncertainty about the model pa-
rameters and structure as probabilities. The hypothetical
probability that, an event, which has already occurred,
would yield a specific outcome, is called likelihood. Prob-
ability, however, refers to the occurrence of future events
while the likelihood refers to past events with known
outcome. The widely held interpretation of probability is
that the numerical probability assigned to a proposition
given particular evidence is a measure of belief in that
proposition given that evidence.
The Bayes’ revision, within a well-structured risk as-
sessment approach to mutually exclusive states (presence/
absence, occurrence/nonoccurrence), may address uncer-
tainty and incomplete knowledge by using the full range
(p  [0,1]) of conditional and decisional (posterior and
Fig. 4. Intersection diagram of clinical decision-making process (repro- path) probabilities and expected preference-based values
duced with permission from [43]).
(e.g., costs, quality-of-life estimates) with their standard
deviations. We provide a simple decision aid where the
probability of ESRD occurrence may range from 0 to 1.
Other approaches such as Markov chain models or arti-lines to monitor or treat, thus decreasing errors and in-
ficial neural networks [13, 20, 26] may employ such con-creasing safety. The systems to support decisions must
cept and compute probability of a clinical outcome (e.g.,address the issues of uncertainty, up-date of knowledge,
ESRD), but they are not always appropriate for classifi-and patient roles (e.g., patient-centered approach in man-
cation purposes at a single clinical evaluation or incorpo-aged care) in clinical science, research, and practice (Fig. 4).
ration of preference-based values and are entirely com-The introduction of uncertainty into the science of
puter dependent [20, 27].logic could be said to have begun almost immediately
Decision tree models and Bayes’ theorem. The mostafter Aristotle founded the subject. In 1937, Black sug-
important contributions of technological procedures to-gested the concept of degree of membership to a set [24].
day are for prognostic and therapeutic decisions. WhatThis represents numerically the degree with which an
practicing clinicians need are scores that would be appli-element belongs to a group of elements or outcomes [25].
cable to patients for whom the outcome is not yet knownIn our case, small membership function values (e.g., pos-
[26, 28]. Accordingly, using the anticipated prevalence orterior probability of ESRD) represent a low degree of
“prior probability” of the outcome, the indices for sen-membership to a set (e.g., low risk of ESRD occurrence).
The Bayesian approach regards all model learning (pa- sitivity and specificity of a test (i.e., marker, risk factor)
can be converted into pragmatic tools for solving prob-rameters, structure) and update of clinical knowledge as
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Fig. 5. Flow-diagram of a ‘‘frequentist’’ ap-
proach to problem decision (from [50] with
modifications). (A) Theoretical example; (B)
REIN study example.
lems with disease diagnosis or progression at the level cesses. Thus, by using two risk factors according to their
of individual patient. The Bayes’ revision of probabilities relative importance (e.g., proteinuria is first and blood
allows a “forward” computation of individual decisional pressure is second), it is possible to better respond to
(posterior) probabilities given the a priori data from the the question whether an individual patient is at high risk
general population where the patient comes from. Regu- of ESRD or not, as early as possible and, within the
lar decision rules consist of the potential predictor for a sequential decision procedure, at the lowest cost [20, 30].
binary or continuous outcome variable. Such rules are A scholarly example of the technique of Bayes’ revi-
usually searched for and employed within a tree analysis, sion would be to apply it to one of the 11 clinical trials
similarly to searching predictors in regression modeling from the pooled analysis [31, 32], for example, the REIN
when the model is intended as a plausible description of study population (N  352 patients) [33]. With 81 cases
how an outcome may depend on a set of factors. Decision with ESRD and base rate of 23.0% (a priori probability
trees are quantitative analysis tools and, in the same time, of ESRD, that is, p[D]  0.23) over median follow-up
graphic models that consist of tree-like structure with of 30 months and sample sensitivity (p[R  | D]) and
branches to represent the possible “predictor-outcome” specificity (1  p[R  | D]) of baseline proteinuria of
combinations. The potential predictors may be introduced 0.68 and 0.59, respectively, the posterior probability of
in a parallel or sequential mode into the tree [20] and, ESRD is 0.331 (p[D | R] or individual risk of 33.1%)
then, related to the outcome. The latter mode concept given that such patient has the factor level  3 g/day. If
is very similar to the application of diagnostic tests that we assume higher specificity and sensitivity of proteinuria
are often done in sequence [26]. In general, testing in (0.95) as in our simulation example (Fig. 1), but the same
sequence is more efficient in terms of the optimal number high base rate of 23%, the individual risk then amounts
of tests to be performed (e.g., risk factors employed) to 85.02% (posterior p[D  | R]  0.850). The in-
than taking several tests at one and the same time. The creased risk, according to this simulation, may be ex-
predictive information from upstream factor decreases plained by more precise detection of both true positive
in significance or impact downstream [29]. Therefore, the and true negative cases, yielding higher overall accuracy
stronger the predictor (e.g., “stratificator”), the earlier to of proteinuria as single predictor of ESRD. The posterior
be introduced into the tree (e.g., to the left) because it probabilities in such decision tree are computed follow-
is assumed that it will retain a relatively higher predictive ing the Bayes’ theorem:
potential along the information flow down the tree (e.g.,
p[D  | R]  p[D] * p[R  | D]/ (p[D]from left to right, to the terminal nodes, see Fig. 3). The
transition between the states (nodes) is assumed to be * p[R  | D]  p[D] * p[R  | D])
a chance process with each transition made with specific
The same Bayesian calculations are presented in a simp-probability (see branches, Figs. 1 to 3) to reach the termi-
ler dichotomized way [34], in frequency format (Fig. 5).nal (output) node with its associated decisional (poste-
Using the United States 1998 base rate of ESRD (1156rior) probability. Then, to obtain specific decisional (i.e.,
patients per million population) and both sensitivity andpath) probabilities, the tree model is solved (i.e., rolled-
specificity of 0.95, we obtain a priori distribution of theback).
outcome similar to that on Fig. 1. Thus, the risk of ESRDThe simulation tree models that support decision and
cost-effectiveness analyses can depict multiple-stage pro- (D) in our theoretical example, given the presence of
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the risk factor (R), is 2.15% [e.g., 0.0215  11/(11  Preference-based values (patient’s quality-of-life estimates
or costs). The clinical decisions need to be individualized,499)]. When the same sensitivity and specificity assump-
especially in cases when they involve choices betweentions are applied to the REIN study example (Fig. 5B),
possible outcomes that may be viewed differently by dif-the individual risk, given the factor, yields to 84.6% [e.g.,
ferent patients (patient’s quality-of-life estimates or “utili-0.8461  77/(7714)] because of the higher ESRD base
ties”) or funding bodies (i.e., costs). For instance, therate of 23.0%.
patient may have preferences not only about how judg-The format of information is one of the main features
ments and decisions are made but also about the healthof the decision maker’s environment. Similar knowledge-
state attributes that are the foci of those judgments andbased exercises in frequency format could be performed
decisions [36, 37].to investigate the role of different assumptions and vary-
A value refers to how desirable a particular outcomeing a priori information in the individual risk (posterior
is, the value of the alternative, whether in United Statesprobability) of ESRD. Such frequency calculations are
dollars, satisfactions, quality-of-life scores, or other ben-more close to the evolved human format for performing
efit. The expected value of each alternative shows its rel-mental computations. Cognitive algorithms developed
ative preferability (importance). Thus, according to util-to deal with absolute frequencies because Homosapiens
ity theory, we are opting for the greatest probability ofexperienced the information from environment in terms
the greatest good. Utility refers to the scale on which theof discrete cases, 5 out of 20 cases rather than 25% (or
preference is measured. Thus, patient preferences (Fig. 4)0.25). However, for the purpose of the decision-making
are elicited and transformed into “utilities,” while theprocess at the individual level, the frequency format is
funding-body preferences are “costs” in monetary terms.informal and unsystematic. For the “frequentist” view,
Decision modeling requires “utilities” to be arbitrary orprobability is a model of long-run relative frequency,
unit-free numbers that represent the relative magnitudewhile in the Bayesian approach to statistical inference,
of the difference between outcomes (e.g., occurrence orprobability is a model of scientific knowledge [30, 35].
nonoccurrence of ESRD), and/or equivalent to a realOne of the great strengths of the Bayesian methodol-
quantity such as survival time or money. The numericalogy is that it allows an expert knowledge, in the form of
range for utilities is conventionally accepted to rangea prior probability distribution, to be formally incorpo-
from 0 (the worst possible outcome or “death”) to 1 (therated in the analysis [35]. In this sense, the Bayesian
best possible outcome or “perfect health”). The reasondecision maker’s estimate can never be wrong. Learning,
for this arbitrary, unit-free numerical assignment is toincluding the Bayesian one, is just the addition of more
enable the decision modeler to multiply the “utility” byinformation. New information may require revision of
its “probability” (also from 0 to 1), with the result being
our beliefs, but it cannot invalidate the judgment made
the expected value of that outcome [38].
on the prior, more limited, information. For instance,
for a patient coming from a high-risk population with a Prior information on ESRD prevalence, risk factors,
base rate of ESRD of 23% and increased proteinuria and patient preferences
(3 g/day), we could expect a risk of ESRD of 33.1%. The main outcome is the occurrence of ESRD in an
Knowing that reduction of proteinuria may translate into average patient in the United States. The prevalence of
population ESRD risk decreasing by 20% to 50% [32], ESRD in the United States is taken from the annual
we could predict that such intervention would decrease report of United States Renal Data System [39, 40]. It
the individual risk in this patient down to 16.5% (e.g., represents the 1998 point prevalence rate of 1156 pa-
6% to 7% below the a priori rate of 23% or, when heavy tients per million population (pmp) and is expressed as
proteinuria is present, 16.5% below the computed poste- a priori probability of ESRD of 0.001156 [0.12%, see
rior risk of 33.1%). However, the practical value of latter above for another informative prior (e.g., the high-rate
estimates, if considered worthwhile, would need to be prevalence estimate of ESRD occurrence from one of
further tested within the frame of randomized clinical our randomized clinical trials in nondiabetic nephropa-
trials. To make monitoring or treatment decisions that thy patients, the REIN study [18, 31])].
involve trade-offs more effective, at least two main com- Two risk factors (proteinuria and systolic blood pres-
ponents are required: (1) updated knowledge about risks sure) are considered as conditionally independent pre-
and benefits of each course of action (knowledge compo- dictors of ESRD. However, since some degree of biologic
nent) and (2) each individual’s preference-based func- interdependence between these factors cannot be defi-
tion (preference component, for example, costs). All ac- nitely ruled out [41], various decision tree scenarios of
tivities (e.g., treatments) rely on the assumption that the input of the risk factor information are evaluated. The
strategies providing the best expected preference-based prevalence of risk factors and their relationship to the
values (e.g., the lowest possible cost-effectiveness ratio) outcome are taken from a pooled analysis of 11 random-
ized trials [31]. The time frame is the average follow-upare always the preferred ones in practice.
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Table 1. Baseline assumptions for the decision tree models of developing end-stage renal disease (ESRD) as based on a hypothetical
population sample of 10,000 persons with two risk factors
Scenario one Scenario two Scenario three
Parameters (simple tree) (parallel tree) (sequential tree)
A priori probability of ESRD (USA, 1998a) 0.001156 0.001156 0.001156
Prevalence of ESRDb
When proteinuria 3 g/day is present (absent) — 16.0% (8.0%) 16.0% (8.0%)
When hypertension is present (absent) — 6.0% (3.0%) 6.0% (3.0%)
Power to detect ESRD
Sensitivity of proteinuria (blood pressure) 0.95 (0.75) — —
Specificity of proteinuria (blood pressure) 0.95 (0.75) — —
1-specificity of proteinuria (blood pressure) 0.05 (0.25) — —
Factors level prevalence (relations between the
risk factorsb)
Prevalence of hypertension when proteinuria
3 g/day is present (absent) — 18.0% (29.0%) 18.0% (29.0%)
Prevalence of proteinuria 3 g/day when
hypertension is present (absent) — 9.0% (8.0%) 9.0% (8.0%)
a 1998 United States point prevalence of reported ESRD of 1156 patients with ESRD as adjusted for age, gender, and race [39]
b Derived from the international pooled analysis of 11 randomized controlled trials [31] and proteinuria as a risk factor is considered “present” if the urinary
protein 3 g/day (i.e., the high-risk level of the factor) and blood pressure as a risk factor is considered “present” when the systolic blood pressure is 140 mm Hg
(i.e., the high-risk level is hypertension). The factors level prevalence is derived from the distributions of the outcome (ESRD) according to the presence/absence
of the two risk factors, consecutively, the different variants of scenario two and scenario three are constructed. This was consistent with the assumed potential of
0.95/0.75 to detect ESRD at univariate analysis used in scenario one as estimated or derived from published studies [31, 42, 43].
duration in these trials (i.e., 2 to 3 years). Risk factors analysis was applied to study the changes when varying
the United States ESRD prevalence (i.e., the base rateare defined as urinary protein excretion rate 3 g/day
(proteinuria) and systolic blood pressure 140 mm Hg or a priori probability of ESRD) [44, 45].
Original data were analyzed by MS Excel 97 (Micro-(hypertension). The risk factors levels are indicated by
“present” (proteinuria or hypertension) and, alterna- soft Corporation, Redmond, WA, USA, 1985-1997, re-
lease SR-1, licensed to Mario Negri Institute for Pharma-tively, “absent” [17, 31] (Figs. 1 to 3). Both sensitivity
and specificity of proteinuria and systolic blood pressure cological Research, Bergamo, Italy). All computations
and graphic presentations were prepared by a specializedas predictors of ESRD are set at 95% and 75%, respec-
tively. Input values are taken from published studies [31, package (“DATA 3.5 for HealthCare” for decision anal-
ysis by TreeAge Software, Inc., Williamstown, MA, USA,42, 43] and, when such prior information could not have
been taken directly from population-based studies, an 1998-2000; release 3.5.7., licensed to Mario Negri Insti-
tute for Pharmacological Research, Bergamo, Italy) [44].estimate was assumed. The estimate of 75% for systolic
blood pressure is based on its lower predictive potential
at univariate analysis, compared to that for proteinuria
RESULTS(a difference being in the range of 20% to 22%) [42, 43].
Decision tree structuresAll input values are later varied and subjected to sensitiv-
ity analysis. Preference-based values, related to the dis- The first decision tree model is constructed to estimate
ease outcome [7], have been introduced into the decision the individual ESRD risk under the scenario in which
tree models from a methodologic/computational view- proteinuria and systolic blood pressure are considered
point only (not shown). The baseline assumptions are separately (simple decision tree, Fig. 1 and Table 2).
presented in Table 1. The second model provides an evaluation of ESRD risk
under the parallel decision tree scenario in which pro-
Scenarios and data analysis teinuria and systolic blood pressure are considered addi-
tive, with a preceding combination of risk factor levels andThree main scenarios of ESRD decision tree models
are investigated. Conditional and decisional probabilities simultaneous input of the a priori information (Table 2).
All three possible variants of the parallel model are ex-are computed by Bayes’ revision and the decision trees
are solved (rolled-back) to obtain path probabilities for plored (only balanced type shown, Fig. 2). The third
ESRD risk model is built in two variants upon the se-each scenario [5, 21, 44] (see above for Bayes’ theorem
and related examples). The posterior probability distri- quential decision tree scenario in which the predictive
potential of proteinuria and systolic blood pressure isbutions (i.e., risk profiles) [44] are also computed (not
shown). To investigate the dependence of the decision explored in alternative order (Table 2). Only one of the
variants is presented graphically (e.g., “proteinuria →tree output upon the a priori information and baseline
assumptions (see above for more details), sensitivity systolic blood pressure”) (Fig. 3).
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Table 2. Simulation by decision tree models: Individual probabilities (risk) of developing end-stage renal disease (ESRD) in the United States
Scenario threeScenario two (parallel tree)a,b
(sequential tree)a
Scenario one Variant Variant Variant
Parameter (simple tree) (PROT → SBP) (SBP → PROT) (balanced) Variant 1 Variant 2
Posterior probability of ESRD (%) when
Proteinuria 3 g/day is present 2.152 — — — — —
Proteinuria 3 g/day is absent 0.006 — — — — —
Hypertension is present 0.346 — — — — —
Hypertension is absent 0.039 — — — — —
Proteinuria 3 g/day is present and
hypertension is present — 5.077 4.755 4.876 3.607 3.607
Proteinuria 3 g/day is present and
hypertension is absent — 0.005 1.442 0.049 0.004 2.152
Proteinuria 3 g/day is absent and
hypertension is present — 0.220 0.005 0.070 0.346 0.004
Proteinuria 3 g/day is absent and
hypertension is absent — 0.024 0.004 0.017 0.039 0.006
Abbreviations are: PROT, proteinuria; SBP, systolic blood pressure.
a Data on the factors level prevalence (relations) are from [31]
b See the text for description of variants
Posterior probabilities (risk) of ESRD occurrence rence of ESRD when both factors are absent (path prob-
ability of 0.4386, terminal node at the last branch, Fig. 2).Scenario one. The single-factor (e.g., proteinuria) de-
The comparison of probability distributions indicatedcision tree risk scenario is illustrated on Fig. 1. The indi-
that the presence of risk factors is associated with thevidual risk (e.g., probability expressed as a percentage)
highest individual risk of ESRD. The sensitivity analysisof an average 1998 United States patient to develop
indicated the dependence of posterior probabilities uponESRD within 2 to 3 years from the time when the heavy
the a priori probability of ESRD (i.e., the prevalenceproteinuria is detected (3 g/day) is 2.15% (the individ-
was varied up to 5.00%).ual risk is 0.006% when proteinuria is 3 g/day). The
Scenario three. The third decision tree model presentschance of such a 1998 United States patient to reach the
also a multidimensional risk assessment scenario, but ofstate of ESRD (path probability) is 0.11%. The most
sequential nature. Assuming the same base-rate of ESRDprobable pathway in the decision tree is of nonoccur-
(point prevalence), the tree is solved with an input ofrence of ESRD when heavy proteinuria is absent (i.e.,
sensitivity and specificity levels as between the risk factors94.89%, terminal node at the last branch, Fig. 1). The
as assessed in a sequential order. The cross-tabulationleast-risky pathway is when the heavy proteinuria is “ab-
analysis of data on proteinuria and systolic blood pres-sent.” When the systolic blood pressure is considered
sure from the 11 randomized trials [40] and the applica-under the same scenario, the individual risk of ESRD
tion of Bayes’ revision have produced the risk factor–in an average hypertensive 1998 United States patient
related conditional probabilities at each branch. Foris 0.35% (individual risk is 0.04% for systolic blood pres-
example, such a conditional (e.g., “intermediate”) proba-sure140 mm Hg, Table 2). The path probabilities (risk)
bility or risk of 3.11% for a patient to be hypertensiveof reaching ESRD are 0.087% and 0.029%, respectively
(i.e., “present”) is obtained when heavy proteinuria is(not shown).
“present” (upper branch in the middle of the tree, Fig. 3).Scenario two. The second decision tree model of ESRD
These conditional probabilities are used, together withrisk is constructed on multidimensional parallel scenar-
posterior probabilities, to derive path probabilities whenios with a simultaneous input of prior information about
the tree is solved (i.e., rolled-back). We analyzed theboth risk factors (i.e., in one and the same phase space).
decision tree in two variants—when the a priori informa-The tree is solved in three input variants: “proteinuria →
tion about systolic blood pressure is introduced into thesystolic blood pressure,” “systolic blood pressure→ pro-
model at a second place, after the data on proteinuriateinuria,” and “balanced.” The analysis revealed the dif-
(Fig. 3) and vice versa (not shown). The most probableferences in posterior probabilities, although negligible
pathways in the sequential tree (e.g., variant 1, see(i.e., an individual risk from 5.08% to 4.76% when both
risk factors are “present,” see Table 2). The least individ- Table 2) are of nonoccurrence of ESRD when the hyper-
tension is “absent” (i.e., the chance of reaching this par-ual risk was found when both factors are “absent” (e.g.,
from 0.024% to 0.004%). Only the third variant (i.e., ticular state is 48.8% and 37.2% at 4th and 8th terminal
nodes, respectively, Fig. 3).balanced input) when proteinuria and systolic blood
pressure are considered additive is shown on Fig. 2. The The comparison of probability distributions has con-
firmed that the presence of both risk factors is associatedmost probable chance in the decision tree is of nonoccur-
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the actual baseline prevalence of heavy proteinuria andwith the highest individual risk of ESRD (3.61%). For
high blood pressure in the reference population of aboutpurposes of external validation, the sensitivity analysis
2000 patients included in a meta-analysis of 11 publishedexplored the variation of the a priori probability of
clinical trials [32]. To this purpose, we considered theESRD within the whole range from 0.050% to 20.050%,
two risk factors (urinary protein excretion rate 3 g/24thus extending the possible application of the above
hours and systolic blood pressure 140 mm Hg) that inmodels beyond the current study population to other
the above study [32] were identified as the strongestcomparable populations at risk for ESRD.
predictors of progression to ESRD in chronic nephropa-
thies. Cost–effectiveness of given interventions or qual-
DISCUSSION ity-of-life adjusted years associated with given outcomes
[50, 51] can be also assessed by this approach. In generalThe renal replacement programs for ESRD have rap-
idly grown throughout the developed world during last terms, a worst outcome (e.g., progression to ESRD) is
associated with higher costs and lower quality of life.decades. About 1 million people, 317,000 Europeans and
283,000 Americans, required renal replacement therapy The Bayesian approach allows precise quantified predic-
tion of both parameters at the individual level, which,in 1996 [46]. In the United States, the number of patients
with ESRD has been projected to nearly double to in addition to helping evaluate clinical outcomes, may
serve to guide clinical decisions by single physicians and650,000 by the year 2010, costing taxpayers $28 billion
annually [47]. In this context, the rapid implementation promote better prevention, intervention, and resource
allocation strategies by health authorities and govern-of effective approaches to predict and prevent ESRD
and its burden on the society becomes an issue of para- ments. In the light of the current programs for managed
care optimization, the closer monitoring and control ofmount importance. According to the principles of clinical
governance [48], the decision-making approach is the identified risk factors, such as heavy proteinuria and sys-
tolic hypertension, may lead to improved outcomes inbest likely way to most objectively evaluate ESRD pro-
gression and optimize therapy at the individual patient individual patients and better quality of life and, in the
same time, limit the overall costs of treatment of chroniclevel (i.e., a patient-centered approach). It may contrib-
ute to the best allocation of resources on a larger scale nephropathies and related complications.
This approach can be applied also to clinical research,(i.e., beyond the local practice settings). This is important
since clinical decisions depend not only on the actual for instance, to achieve balanced distribution of recog-
nized determinants of outcome in different treatmentindividual health status and preference-based values
such as quality of life and/or costs but also on the avail- groups of a randomized trial or to identify, a priori, po-
tential targets of treatment or experimental interventions.able access to beneficial health care provisions. Thus,
approaches to predict patient outcomes relative to given Actually, heavy proteinuria and increased blood pres-
sure are manageable risk factors. Compelling evidencerisk factors and/or therapeutic interventions are needed
to establish priority settings and maximize efficiency and is available that in chronic nephropathies, the reduction
of proteinuria, in particular with drugs that inhibit theeffectiveness of the decision-making processes, the final
target being the optimization not only of individual care, renin-angiotensin system, may translate in substantial
long-term renoprotection, with risk of progression tobut also of the use of available, and unfortunately, finite
resources (i.e., “justice as efficiency”) [49]. This applies ESRD decreasing by 20% to 50% in different groups of
patients [32].specifically to ESRD, due to the enormous costs of renal
replacement therapy and the concern that these will soon For both purposes the decision tree probabilistic ap-
proach is superior to the conventional statistical models,outstrip the available resources. At the present time, the
costs and complexity of renal replacement therapy are as it is not constrained by sample size, normality of dis-
tributions or underlying assumptions for specific rela-unaffordable in most of developing countries.
In this theoretical study, we presented scenarios of tionships between variables. The decision probabilistic
approaches can powerfully model complex nonlinear re-clinical decision-making approaches based on the Bayes’
theorem to assess the individual risk of ESRD on the lationships in different subgroups of the population [37].
Of course, the final outputs strongly depend on the choicebasis of the prevalence of the disease in a reference pop-
ulation [31, 32] and the presence/absence of predefined of the risk factors used as input variables and underlying
assumptions. These can be assessed through expert opin-risk factors. We introduced the notion of risk of ESRD
at the individual level and explored the possibility to ions [11] or better, through multifactorial analyses [7]
or, as in our case, from publicly available data on preva-assess the individual risk profile on the basis of different
combinations of risk factors. To exemplify the practical lences (e.g., ESRD rate), sensitivities, and specificities
[32, 43].application of this approach, we explored the individual
risk (as percentage) for an average patient in the United To test the influence of the initial assumptions of our
models, we performed sensitivity analysis. In most variantsStates to develop ESRD by using decision tree models
that assumed a priori information on risk factors from of the models, this specific type of analysis indicated a
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clear and strong dependence of the posterior probabili- tion or complication of the first one (for instance, this
ties (risk of ESRD) on the a priori probability of ESRD. may be the case of the occurrence of proteinuria in a
Moreover, finding that for different probabilities of ESRD patient with a previous history of chronic hypertension)
in the reference population and different combinations and, at best, the first and second are going to predict an
of selected variables, such as heavy proteinuria and sys- outcome that is already and largely determined by the
tolic hypertension, confirmed that a decision tree, Bayes- former. Another possibility is that information about
ian-based model, provided remarkably precise estimates relevant risk factors may become available at the same
of the individual risk and further strengthened the relia- time. In such case, the input order can reflect the relative
bility and the practical applicability of the approach. importance of the variables in order to intentionally in-
A corollary of this concept is that the same constella- crease the predictive value of the variable that, on the
tion of risk factors in a given individual patient may basis of available experimental and clinical data, is ex-
predict quite different outcomes according to different pected to have a major impact on disease outcome. This
disease prevalences in different reference populations. may explain why the predicted outcome may differ if
Thus, the simultaneous presence of heavy proteinuria and the same individual variables are entered in a different
hypertension may result in an individual risk that in order according to a temporal or a relevance criterion.
patients coming from high-risk populations such as Afri-
can Americans, Aborigine Australians, or Pima Indians
may exceed that predicted in an average United States CONCLUSION
patient. The exact estimate of the risk in specific popula-
By decision tree Bayesian modeling, uncertain primarytions does also allow a more precise prediction and quan-
data can be processed and unstructured clinical problemstification of the clinical and social impact of the interven-
solved. Estimates of quality of life and costs, associatedtions aimed to treat or control the considered risk factors
with ESRD, can be also provided within the frame of aat individual level. For instance, whereas in an average
formal individual-level risk assessment. Such outputs areUnited States patient controlling both heavy proteinuria
and systolic blood pressure may decrease the individual achievable with very simple, basic information concern-
risk of ESRD from 3.61% to 1.80%, in a patient from ing disease epidemiology in a given population and de-
a high-risk population (for instance, because of the con- mographic, clinical, and laboratory data that can be easily
comitance of renal insufficiency [33]) controlling even available at the first patient evaluation.
heavy proteinuria alone may decrease the individual risk This well-structured problem-solving modeling system
from 33.1% to 16.5% (see discussion above). developed to predict outcomes might find broader appli-
Decision tree scenarios, however, may also vary ac- cation to identify high-risk patients and predict disease
cording to different flows of information (i.e., different progression and outcomes also in other areas of medicine.
order of input when calculating event probabilities and The conceptual framework, if expanded, may have major
related utilities) (see assumptions, Table 1). In compari-
clinical, economic, and scientific implications for suchson to parallel simulations (scenario two), the sequential
pathologies as hypertension, diabetes and cardiovascularmodel is based on more uniform assumptions in the view
disease that are common worldwide and exact an enor-of the information flow and sequence of tests (i.e., input
mous burden on health care systems.of risk factors data, computation of conditional probabil-
ities), which may limit random fluctuations of the output
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